JP2021521119A5 - - Google Patents
Info
- Publication number
- JP2021521119A5 JP2021521119A5 JP2020555099A JP2020555099A JP2021521119A5 JP 2021521119 A5 JP2021521119 A5 JP 2021521119A5 JP 2020555099 A JP2020555099 A JP 2020555099A JP 2020555099 A JP2020555099 A JP 2020555099A JP 2021521119 A5 JP2021521119 A5 JP 2021521119A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- buffer
- chromatography
- ultrafiltration
- antibody construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024056116A JP2024075786A (ja) | 2018-04-12 | 2024-03-29 | 安定なタンパク質組成物を製造する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656687P | 2018-04-12 | 2018-04-12 | |
| US62/656,687 | 2018-04-12 | ||
| PCT/US2019/024683 WO2019199476A1 (en) | 2018-04-12 | 2019-03-28 | Methods for making stable protein compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024056116A Division JP2024075786A (ja) | 2018-04-12 | 2024-03-29 | 安定なタンパク質組成物を製造する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521119A JP2021521119A (ja) | 2021-08-26 |
| JP2021521119A5 true JP2021521119A5 (enExample) | 2022-03-30 |
| JP7465215B2 JP7465215B2 (ja) | 2024-04-10 |
Family
ID=66251859
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555099A Active JP7465215B2 (ja) | 2018-04-12 | 2019-03-28 | 安定なタンパク質組成物を製造する方法 |
| JP2024056116A Pending JP2024075786A (ja) | 2018-04-12 | 2024-03-29 | 安定なタンパク質組成物を製造する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024056116A Pending JP2024075786A (ja) | 2018-04-12 | 2024-03-29 | 安定なタンパク質組成物を製造する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210163531A1 (enExample) |
| EP (1) | EP3774894A1 (enExample) |
| JP (2) | JP7465215B2 (enExample) |
| KR (1) | KR102791798B1 (enExample) |
| CN (1) | CN111971302A (enExample) |
| AU (2) | AU2019250882B2 (enExample) |
| BR (1) | BR112020020854A2 (enExample) |
| CA (1) | CA3096374A1 (enExample) |
| CL (1) | CL2020002597A1 (enExample) |
| EA (1) | EA202092464A1 (enExample) |
| IL (1) | IL277797B1 (enExample) |
| MA (1) | MA52204A (enExample) |
| MX (2) | MX2020010724A (enExample) |
| SG (1) | SG11202010100QA (enExample) |
| WO (1) | WO2019199476A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2877589B1 (en) | 2012-07-26 | 2024-03-06 | Momenta Pharmaceuticals, Inc. | Glycoproteins with anti-inflammatory properties |
| WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| WO2015057622A1 (en) | 2013-10-16 | 2015-04-23 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| US20220396599A1 (en) * | 2019-11-13 | 2022-12-15 | Amgen Inc. | Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules |
| KR20230024891A (ko) * | 2020-06-11 | 2023-02-21 | 2세븐티 바이오, 인코포레이티드 | 바이러스 벡터 제조 방법 |
| US12286451B2 (en) | 2020-11-23 | 2025-04-29 | Medtech Products Inc. | Borate ester complexes of α-hydroxy carboxylic acids and their conjugate base buffers |
| EP4259192A4 (en) * | 2020-12-09 | 2024-11-20 | Dr. Reddy's Laboratories Limited | STABLE AQUEOUS BUFFER-FREE FORMULATION OF AN INTEGRIN ANTIBODY |
| TW202432179A (zh) * | 2023-02-08 | 2024-08-16 | 瑞士商百濟神州瑞士有限責任公司 | 用於高度濃縮的ｐｄ１抗體溶液的超濾／滲濾方法 |
| CN117088974B (zh) * | 2023-08-14 | 2024-02-13 | 武汉健昊生物科技有限公司 | 一种抗体保存液 |
| CN121587349A (zh) * | 2026-01-28 | 2026-03-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | 高浓度无菌乳铁蛋白液及其制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| EP1789072A2 (en) * | 2004-05-10 | 2007-05-30 | Curagen Corporation | Prophylactic and therapeutic uses of fgf-20 in radiation protection |
| US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| DK1814913T3 (en) | 2004-11-05 | 2015-09-28 | Univ Leland Stanford Junior | ANTIBODY-INDUCED CELL membrane damage. |
| EP2397498A3 (en) | 2005-07-18 | 2013-11-27 | Amgen, Inc | Human anti-B7RP1 neutralizing antibodies |
| US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| PL2188313T3 (pl) | 2007-08-21 | 2018-04-30 | Amgen, Inc. | Białka wiążące ludzki antygen c-fms |
| US8420081B2 (en) * | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| US20130195888A1 (en) * | 2007-11-30 | 2013-08-01 | Abbvie | Ultrafiltration and diafiltration formulation methods for protein processing |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| PT2403865E (pt) * | 2009-03-03 | 2015-11-18 | Grifols Therapeutics Inc | Métodos de preparação de plasminogénio |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| US20120076779A1 (en) | 2010-09-17 | 2012-03-29 | Baxter Healthcare S.A. | STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph |
| ES2381828B1 (es) | 2012-03-20 | 2012-11-16 | Grifols, S.A. | PROCEDIMIENTO PARA OBTENER UNA COMPOSICION DE IgG MEDIANTE TRATAMIENTO TERMICO |
| US20140154270A1 (en) * | 2012-05-21 | 2014-06-05 | Chen Wang | Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography |
| CN112126634A (zh) | 2013-01-09 | 2020-12-25 | 夏尔人类遗传性治疗公司 | 含用于纯化芳基硫酸酯酶a的方法 |
| CA2906737C (en) | 2013-03-15 | 2023-08-15 | Amgen Inc. | Human pac1 antibodies |
| EP3102603A1 (en) * | 2014-02-07 | 2016-12-14 | Novo Nordisk A/S | Antibody process |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| WO2018033482A1 (en) | 2016-08-17 | 2018-02-22 | Boehringer Ingelheim International Gmbh | Process for the preparation of highly concentrated liquid formulations containing biomolecules |
| GB201707484D0 (en) * | 2017-05-10 | 2017-06-21 | Argenx Bvba | Method of preparing ph-dependent antibodies |
| EP3446710A1 (en) * | 2017-08-25 | 2019-02-27 | Glenmark Pharmaceuticals S.A. | Methods of inactivating viral contaminants |
| GB2636539A (en) * | 2023-03-16 | 2025-06-25 | Univ Of Sunderland | Wound dressing |
-
2019
- 2019-03-28 MX MX2020010724A patent/MX2020010724A/es unknown
- 2019-03-28 KR KR1020207032156A patent/KR102791798B1/ko active Active
- 2019-03-28 MA MA052204A patent/MA52204A/fr unknown
- 2019-03-28 WO PCT/US2019/024683 patent/WO2019199476A1/en not_active Ceased
- 2019-03-28 SG SG11202010100QA patent/SG11202010100QA/en unknown
- 2019-03-28 JP JP2020555099A patent/JP7465215B2/ja active Active
- 2019-03-28 EP EP19719397.2A patent/EP3774894A1/en active Pending
- 2019-03-28 BR BR112020020854-0A patent/BR112020020854A2/pt unknown
- 2019-03-28 EA EA202092464A patent/EA202092464A1/ru unknown
- 2019-03-28 US US17/046,662 patent/US20210163531A1/en active Pending
- 2019-03-28 IL IL277797A patent/IL277797B1/en unknown
- 2019-03-28 AU AU2019250882A patent/AU2019250882B2/en active Active
- 2019-03-28 CN CN201980025383.9A patent/CN111971302A/zh active Pending
- 2019-03-28 CA CA3096374A patent/CA3096374A1/en active Pending
-
2020
- 2020-10-08 CL CL2020002597A patent/CL2020002597A1/es unknown
- 2020-10-09 MX MX2025009986A patent/MX2025009986A/es unknown
-
2024
- 2024-03-29 JP JP2024056116A patent/JP2024075786A/ja active Pending
-
2026
- 2026-01-14 AU AU2026200233A patent/AU2026200233A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521119A5 (enExample) | ||
| AU2026200233A1 (en) | Methods for making stable protein compositions | |
| TWI459961B (zh) | 長效人類生長激素共軛物之液態配方 | |
| JP5153532B2 (ja) | モノクローナル抗体又はポリクローナル抗体の安定な凍結乾燥された医薬製剤 | |
| EP2485766B1 (fr) | Excipient stabilisant pour vaccins a virus entiers inactifs | |
| JP2020079242A (ja) | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 | |
| KR101335765B1 (ko) | 지속형 에리스로포이에틴 결합체의 액상 제제 | |
| EP2258402A2 (en) | Dried composition | |
| NZ286046A (en) | Stable transglutaminase (factor xiii) preparations | |
| US8216588B2 (en) | Lyophilized preparation comprising influenza vaccine, and method for preparation thereof | |
| JP2021503485A (ja) | ＶＥＧＦＲ−Ｆｃ融合タンパク質製剤 | |
| CN114288254A (zh) | 长效人生长激素缀合物的制剂 | |
| JP2022513142A (ja) | タンパク質処理のための賦形剤化合物 | |
| KR20150074167A (ko) | Ｐｅｇ 인터페론 알파-2ｂ의 안정한 약학 조성물 | |
| CN103611162B (zh) | 人凝血因子ⅷ冻干保护剂及其制备方法 | |
| Prasad et al. | Innovation in stabilization of biopharmaceuticals | |
| CA3168727A1 (en) | Daptomycin formulation with branched aiphatic amino acid | |
| US20250312436A1 (en) | Stabilization of virus-based therapeutic agent | |
| WO2025226754A1 (en) | Method for predicting osmolality of protein solutions | |
| CA2966758C (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| KR19990075253A (ko) | 약학적으로 안정한 인터페론 제 | |
| MXPA01002206A (en) | Stabilized granulocyte colony stimulating factor |